Nick and Fiona talk to Greig Pickhaver about the new SBS show Secrets Of Our Cities about the history of Australian ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.

Gilead has settled patent disputes with three generic companies for Biktarvy, per a Yahoo Finance report. Gilead settlement agreements are with Lupin, Cipla and Laurus Labs, who had filed abbreviated ...

On Oct. 6, Gilead Sciences GILD announced a settlement with three generic manufacturers, securing an agreement for them not to launch a generic version of the firm’s HIV drug Biktarvy in the United ...

Gilead Sciences has bolted another asset onto the virology engine that powers the company, paying (PDF) Health Hope Pharma $10 million upfront for global rights to a candidate in a limited set of ...

Judge said no evidence to support claims of kickbacks on Harvoni, Sovaldi Whistleblower will appeal, his lawyers say Gilead settled claims of kickbacks on HIV drugs earlier this year Sept 12 (Reuters) ...

While Gilead Sciences previously ponied up hundreds of millions of dollars to resolve kickback allegations related to its HIV business, the company this week triumphed over a whistleblower lawsuit ...

Gilead Sciences broke ground on its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters in California. This milestone ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised ...

Gilead raises full-year outlook, cites strong HIV drug sales Quarterly earnings flat, revenue up 2% to $7.1 billion HIV sales rise 7% to $5.1 billion Aug 7 (Reuters) - Gilead Sciences (GILD.O), opens ...